JointHealth™ express August 17, 2017
JointHealth™ Correction
The 2017 JointHealth™ Arthritis Medications Report Card and Medications Guide referred incorrectly to the indications approved for etanercept (Erelzi®)
A biosimilar version of etanercept based upon the reference product etanercept (Enbrel®), etanercept (Erelzi®) was issued a Notice of Compliance by Health Canada on April 5, 2017 for the treatment of patients with rheumatoid arthritis, ankylosing spondylitis and juvenile idiopathic arthritis.
We apologize for this oversight. Please kindly make this correction to the printed copy you may have recently received in the mail if you are a print subscriber.
Arthritis Consumer Experts
JointHealth™ Correction
The 2017 JointHealth™ Arthritis Medications Report Card and Medications Guide referred incorrectly to the indications approved for etanercept (Erelzi®)
A biosimilar version of etanercept based upon the reference product etanercept (Enbrel®), etanercept (Erelzi®) was issued a Notice of Compliance by Health Canada on April 5, 2017 for the treatment of patients with rheumatoid arthritis, ankylosing spondylitis and juvenile idiopathic arthritis.
We apologize for this oversight. Please kindly make this correction to the printed copy you may have recently received in the mail if you are a print subscriber.
Arthritis Consumer Experts